Across TCGA pan-cancer cohorts, RPS6KA2-AS1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPS6KA2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPS6KA2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS6KA2-AS1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, STAD, and THCA are the cancer types where RPS6KA2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS6KA2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.111	<.001	10	view →
STAD	All	II,III,IV	+0.134	.003	6	view →
THCA	All	All	−0.094	<.001	5	view →
BLCA	Male	All	+0.214	.039	2	view →
CHOL	All	All	+0.078	.037	1	view →
KICH	All	All	−0.018	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: RPS6KA2-AS1 RNA expression & survival · all RPS6KA2-AS1 data types